/
Markets
Crypto
News
Forecasts
Forex Brokers
Calendars
Macro Data
About us
Commodity Prices
Currency Rates
Cryptocurrency Prices
Global Market Indices
Stock Prices
ETF Prices
Cryptocurrency Prices
Crypto Exchanges
Crypto Wallets
Cryptocurrency News
Cryptocurrency Forecasts
Commodity News
Forex News
Crypto News
Stock Market News
Economic News
Opinions
Broker News
Commodities
Forex
Crypto
Indices
Natural Gas Forecasts
Gold Forecasts
WTI Crude Oil Forecasts
S&P 500 Forecasts
Forex Brokers Reviews
Best Brokers Guides
Compare Forex Brokers
Best Forex Brokers
Best Forex Platforms
Best MT4 Brokers
Best for Trading Gold
Best Brokers in Australia
Best Brokers for Beginners
Best Brokers in UK
Stock Brokers
Economic Calendar
Earnings Calendar
Splits Calendar
Dividends Calendar
Holiday Calendar
IPO Calendar
Stock Screener
Currency Converter
Global Macro indicators
Sovereign Credit Ratings
Global Major Indicators
Interest Rates
United States Indicators
China Indicators
Australia Indicators
Euro Area Indicators
About us
Contact Us
Terms Of Use
Become A Contributer
EUR/USD
+0.07%
Natural Gas
-3.95%
Gold
N/A
BTC
N/A
ETH
N/A
SPX
-0.11%
VIX
N/A
Economic Calendar
EUR/USD
+0.07%
Natural Gas
-3.95%
Gold
N/A
BTC
N/A
ETH
N/A
SPX
-0.11%
VIX
N/A
Economic Calendar
BTC
N/A
ETH
N/A
XRP
N/A
ADA
N/A
SOL
N/A
Review
Review
Review
October PPI Rises 0.2%, Supporting Fed Rate Cut Hopes as Inflation and Jobs Steady
about 2 hours ago
Disney’s Streaming Fuels Optimism; PPI Data May Forecast Fed’s Next Steps
about 3 hours ago
Eurozone Economy Expands by 0.4% in Q3 2024 but US Tariff Threat Remains
about 6 hours ago
UK Wage Growth and Jobless Rate Rise, Fueling BoE Rate Path Uncertainty
2 days ago
Michigan Consumer Sentiment Rises To 73.0, Beating Analyst Expectations
6 days ago
Germany: Stable Government Needed to Address Shifts in US Policy and Raise Growth Outlook
6 days ago
Meme Coin Analysis: Market Correction Impacts Bonk, Dogwifhat, Popcat Rally Towards All-Time Highs
9 minutes ago
Dow Jones Gains as Disney Earnings Impress; Nasdaq & S&P 500 Face Inflation Fears
about 1 hour ago
Natural Gas Price Outlook – Natural Gas Continues to Look Strong
about 1 hour ago
Gold Price Outlook – Gold Continues to See Pressures
about 1 hour ago
Crude Oil Price Outlook – Crude Continues to See Support at The Same Area
about 1 hour ago
Bitcoin Price Outlook – Bitcoin Continues to Look Strong After Big Move
about 2 hours ago
Quick Links
:
Forecasts
Economic Calendar
Commodities
Trade Now
ad
ad
Advertisement
Advertisement
home
stocks
GILD
profile
Gilead Sciences, Inc.
Follow
GILD
(
Nasdaq - US
)
Open
92.18
-0.45 (-0.49%)
in
:
usd
•
As of: Nov 14, 2024 11:17
UTC -5
Open
92.45
High
92.45
Low
91.30
Overview
News & Analysis
Profile
Financials
Advanced Chart
History
Earnings
Dividends
About
Gilead Sciences, Inc.
CEO
Daniel P. O¿Day
Headquarters
333 lakeside drive
foster city, ca 94404, united states
Auditor
Ernst & Young LLP
Employees
18,000
Share Holders
1,396
Website
www.gilead.com
Industry
biotechnology
Sector
health technology
Company Overview
Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.
Gilead Sciences, Inc.
Statistics
Valuation Measures
Market Capitalization
2
114.76B
Enterprise Value
134.37B
Enterprise Value/EBITDA
(ttm)
37.48
Price to Earnings Ratio
(ttm)
21.30
Price to Book
(mrq)
6.39
Price to Sales
(ttm)
4.15
Price to Cash
(ytd)
10.55
Profitability
Gross Margin
(ttm)
75.75%
Operating Margin
(ttm)
19.67%
Profit Margin
(ttm)
2.96%
Return on Equity
(ttm)
29.00%
Return on Invested Capital
(ttm)
1.50%
Return on Assets
(ttm)
9.83%
Income Statement
Revenue
(ttm)
28.30B
Revenue Per Share
(ttm)
22.71
Gross Profit
(ttm)
21.54B
EBITDA
(ttm)
3
3.58B
Net Income Avi to Common
(ttm)
127.00M
Diluted EPS
(ttm)
0.09
Share Statistics
Beta (5Y Monthly)
0.17
52-Week Change
28.50%
S&P500 52-Week Change
32.95%
S&P500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding
1
1.25B
Dividend Yield
3.26%
Float
4
1.24B
%
Held by Insiders
0.16%
%
Held by Institutions
83.67%
Balance Sheet
Total Cash
(mrq)
5.04B
Total Cash Per Share
(mrq)
4.04
Total Debt
(mrq)
24.64B
Total Debt/Equity
(mrq)
128.32%
Current Ratio
(mrq)
1.14%
Quick Ratio
(mrq)
0.82%
Book Value Per Share
(mrq)
14.60
Cash Flow
Operating Cash Flow Per Share
(ytd)
2.83
Free Cash Flow
(ytd)
3.31B
Table Key
mrq
=
Most Recent Quarter
ttm
=
Trailing Twelve Months
ytd
=
Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.
1
Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2
Market Cap is calculated using total shares outstanding and the most recent share price.
3
EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4
The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Sponsored
Sponsored
This Section / Page contains links to the 3rd party websites of our top partners from whom we may receive compensation.
Trade With A Regulated Broker